Search results
Results from the WOW.Com Content Network
2,3-Methylenedioxymethamphetamine (2,3-MDMA) is a positional isomer of the recreational drug 3,4-MDMA (commonly known as Ecstasy or Molly). [1] See also
The MDMA is often taken first and the 2C-B after the end of the MDMA peak (h+2/h+2.½). [11] The 2C-B is supposed to help the empathogenic effect of the MDMA last longer. 2C-B: DXM: Nexuswalk [12] Nexuswalk Nexus (slang for 2C-B) + Robowalk (slang for walking on DXM), similar to Nexusflipping 2C-B: LSD: Gnome flip 2C-E: LSD: MDMA: Haychmaich ...
Approximately 60% of MDMA users experience withdrawal symptoms when they stop taking MDMA. [75] Some of these symptoms include fatigue, loss of appetite, depression, and trouble concentrating. [ 75 ] Tolerance to some of the desired and adverse effects of MDMA is expected to occur with consistent MDMA use. [ 75 ]
Some ingredients such as caffeine, creatine and β-alanine are found in nearly all pre-workout blends, but each branded product is a "proprietary blend" with an average of 18 different ingredients, the exact composition and proportions of which can vary widely between different products.
The duration of MDA is longer than that of MDMA, about 8 hours for MDA versus 6 hours for MDMA. [ 2 ] [ 38 ] The elimination half-life of MDA is 10.9 hours. [ 2 ] Differences in the duration of MDA versus MDMA may be due pharmacodynamics rather than pharmacokinetics.
Anxiolytics are medicinally used to reduce the symptoms of anxiety, and sometimes insomnia. Example: benzodiazepines such as Xanax and Valium; barbiturates. Empathogen–entactogens alter emotional state, often resulting in an increased sense of empathy, closeness, and emotional communication. Example: MDMA (ecstasy), MDA, 6-APB, AMT
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Methylone is a slight modification of 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy). It was first synthesized by the chemists Peyton Jacob III and Alexander Shulgin in 1996 for potential use as an antidepressant. [ 4 ]